

Wellnex Life Limited (ASX:WNX)**Trading Update YTD FY25****Announcement highlights**

- Total sales for Jul-Nov FY25 increased to \$8.92 million, up 66% compared to the same period for FY24 (\$5.36 million).
- Strong brand sales in the period, increasing 137% in FY25 (\$6.47 million) compared to the same period in FY24 (\$2.73 million)
- Momentum increasing, with 321% increase of sales recorded for November 2024 (\$3.16 million).

Wellnex Life Limited (ASX:WNX) (“Wellnex” or “the Company”) is pleased to provide a company update for the July to November period, which included a record month in November with sales of \$3.16 million.

Sales in November increased to \$3.16 million, up 321% compared to November 2023 (\$0.75 million), with growth coming across the whole business.

	November 2023	November 2024	% Change
Brands	\$0.56 million	\$1.52 million	+171%
IP Licensing	\$0.19 million	\$1.64 million	+763%
Total	\$0.75 million	\$3.16 million	+321%

After a slow start for FY25, Wellnex is now seeing continued growth with sales for the first 5 months of FY25 (\$8.92 million) up 66% compared to the same period for FY24 (\$5.36 million). Sales in FY24 also included \$0.51 million in brokerage revenue (which the business has exited), so on a like-for-like basis the increase in sales was 84% for in this period compared to the same period in FY24.

	Jul – Nov 2023	Jul – Nov 2024	% Change
Brands	\$2.73 million	\$6.47 million	+137%
IP Licensing	\$2.12 million	\$2.45 million	+15%
Brokerage	\$0.51 million	\$0	-100%
Total	\$5.36 million	\$8.92 million	+66%

Wellnex Life Limited

Building 2, Level 3, Suite 69, 574 Plummer Street, Port Melbourne VIC Australia
info@wellnexlife.com.au Phone: +61 3 8399 9419

The board anticipates this momentum to continue for the remainder of FY25, on the back of the ongoing expansion of Wellnex' brands in both distribution and awareness, the global expansion of the Haleon arrangement and the newly launched prescription-only medicinal cannabis brand.

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNX)

For further information, please contact:

Wellnex Life Limited (ASX:WNX)

George Karafotias

Chief Executive Officer

P: +61 3 8399 9419

E: george.k@wellnexlife.com.au

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/